Nuvilex Could Be Beneficiary of New Medical Marijuana Legislation
(firmenpresse) - BALTIMORE, MD -- (Marketwired) -- 05/06/13 -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that (OTCQB: NVLX) could be positioned as a beneficiary of the State of Maryland becoming the 19th state in the U.S. to approve a medical marijuana program. Nuvilex is an international firm engaged in live-cell encapsulation technology to treat pancreatic cancer along with the development and study of the use of medical marijuana for the treatment of oncology patients.
As each state in the U.S. passes medical marijuana legislation, the size of the industry dramatically grows. In particular, adding Maryland to the mix is a major plus for Nuvilex since it is headquartered in Silver Spring, Maryland. Moreover, the state is a hotbed of medical research for not just the region but the entire nation due to access to world-class medical research institutions such as Johns Hopkins University and the National Institute of Health.
Not to be outdone, 9 other states have legislation pending before their governing bodies regarding the medical marijuana issue, including the 3rd most populous state in the country, New York. Proponents of medical marijuana programs in the Empire State have been gaining steam of late and it appears that legislation could indeed pass very soon. Other states in this category are Florida and Illinois, the 4th and 5th largest states in the U.S., respectively. Once these 3 states come on line, over half of the country's population will reside in states that have passed some form of medical marijuana legislation.
Such an event would serve as a real catalyst for the industry. Clearly, that milestone would have a major impact on stocks such as Nuvilex that have business lines focused on medical marijuana research.
To view a summary of Nuvilex reports or download the reports in their entirety, please visit
Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit .
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit .
(OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit:
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 06.05.2013 - 13:10 Uhr
Sprache: Deutsch
News-ID 256402
Anzahl Zeichen: 0
contact information:
Town:
BALTIMORE, MD
Kategorie:
Investment Services & Trading
Diese Pressemitteilung wurde bisher 148 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nuvilex Could Be Beneficiary of New Medical Marijuana Legislation"
steht unter der journalistisch-redaktionellen Verantwortung von
Goldman Small Cap Research, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
